Axsome Therapeutics Inc (NASDAQ: AXSM) on Tuesday, soared 2.28% from the previous trading day, before settling in for the closing price of $107.66. Within the past 52 weeks, AXSM’s price has moved between $64.11 and $139.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 42.50%. With a float of $40.45 million, this company’s outstanding shares have now reached $49.22 million.
Let’s look at the performance matrix of the company that is accounted for 683 employees. In terms of profitability, gross margin is 91.49%, operating margin of -62.54%, and the pretax margin is -64.37%.
Axsome Therapeutics Inc (AXSM) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Axsome Therapeutics Inc is 17.84%, while institutional ownership is 76.48%. The most recent insider transaction that took place on May 27 ’25, was worth 395,512. In this transaction Director of this company sold 3,750 shares at a rate of $105.47, taking the stock ownership to the 50,387 shares. Before that another transaction happened on May 28 ’25, when Company’s Director sold 3,750 for $103.43, making the entire transaction worth $387,862. This insider now owns 46,637 shares in total.
Axsome Therapeutics Inc (AXSM) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 42.50% per share during the next fiscal year.
Axsome Therapeutics Inc (NASDAQ: AXSM) Trading Performance Indicators
Axsome Therapeutics Inc (AXSM) is currently performing well based on its current performance indicators. A quick ratio of 1.96 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.77, a number that is poised to hit -1.05 in the next quarter and is forecasted to reach 1.71 in one year’s time.
Technical Analysis of Axsome Therapeutics Inc (AXSM)
Axsome Therapeutics Inc (NASDAQ: AXSM) saw its 5-day average volume 0.71 million, a negative change from its year-to-date volume of 0.85 million. As of the previous 9 days, the stock’s Stochastic %D was 69.52%. Additionally, its Average True Range was 3.48.
During the past 100 days, Axsome Therapeutics Inc’s (AXSM) raw stochastic average was set at 51.59%, which indicates a significant decrease from 87.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 26.04% in the past 14 days, which was lower than the 56.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $107.90, while its 200-day Moving Average is $101.45. Nevertheless, the first resistance level for the watch stands at $111.58 in the near term. At $113.06, the stock is likely to face the second major resistance level. The third major resistance level sits at $114.70. If the price goes on to break the first support level at $108.46, it is likely to go to the next support level at $106.82. The third support level lies at $105.34 if the price breaches the second support level.
Axsome Therapeutics Inc (NASDAQ: AXSM) Key Stats
Market capitalization of the company is 5.42 billion based on 49,236K outstanding shares. Right now, sales total 385,690 K and income totals -287,220 K. The company made 121,460 K in profit during its latest quarter, and -59,410 K in sales during its previous quarter.
